文献速递瓣膜病与结构性心脏病

经导管主动脉瓣植入与外科主动脉瓣置换治疗症状性重度主动脉瓣狭窄的更新荟萃分析

Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis.
PubMed 文献 · Eur Heart J · 2019-01-01

该荟萃分析纳入7项随机对照试验共8020例症状性重度主动脉瓣狭窄患者,比较经导管主动脉瓣植入(TAVI)与外科主动脉瓣置换(SAVR)的安全性及有效性。结果显示TAVI与2年内全因死亡率和卒中风险显著降低相关,且该效应在不同外科风险谱和不同瓣膜类型中一致;SAVR则与较低的主要血管并发症和永久起搏器植入风险相关。

要点

  • TAVI与SAVR相比,2年内全因死亡率显著降低(HR 0.88,95%CI 0.78-0.99,P=0.030)。
  • TAVI组卒中风险显著低于SAVR组(HR 0.81,95%CI 0.68-0.98,P=0.028)。
  • SAVR组主要血管并发症和永久起搏器植入风险显著低于TAVI组。

核心结论

  • 与SAVR相比,TAVI与2年内全因死亡率和卒中风险降低相关,且该效应在不同基线外科风险和不同经导管心脏瓣膜系统类型中一致。

研究设计与样本

  • 本研究为注册于PROSPERO(CRD42016037273)的荟萃分析,纳入7项比较TAVI与SAVR治疗重度主动脉瓣狭窄的随机对照试验,共随机分配8020例参与者至TAVI组(4014例)和SAVR组(4006例)。
  • TAVI组合并平均STS评分在高危、中危和低危手术风险试验中分别为9.4%、5.1%和2.0%。

主要发现

  • TAVI与SAVR相比,全因死亡率显著降低(HR 0.88,95%CI 0.78-0.99,P=0.030),且该效应在整个外科风险谱中一致(交互作用P=0.410),与经导管心脏瓣膜系统类型无关(交互作用P=0.674)。
  • TAVI组卒中风险显著低于SAVR组(HR 0.81,95%CI 0.68-0.98,P=0.028)。
  • SAVR组主要血管并发症风险显著低于TAVI组(HR 1.99,95%CI 1.34-2.93,P=0.001)。
  • SAVR组永久起搏器植入风险显著低于TAVI组(HR 2.27,95%CI 1.47-3.64,P<0.001)。

临床怎么用

  • 在症状性重度主动脉瓣狭窄患者中,TAVI可作为SAVR的替代选择,尤其关注其降低全因死亡率和卒中的获益。
  • 临床决策时需权衡TAVI较低的死亡和卒中风险与SAVR较低的血管并发症和永久起搏器植入风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Owing to new evidence from randomized controlled trials (RCTs) in low-risk patients with severe aortic stenosis, we compared the collective safety and efficacy of transcatheter aortic valve implantation (TAVI) vs. surgical aortic valve replacement (SAVR) across the entire spectrum of surgical risk patients. METHODS AND RESULTS: The meta-analysis is registered with PROSPERO (CRD42016037273). We identified RCTs comparing TAVI with SAVR in patients with severe aortic stenosis reporting at different follow-up periods. We extracted trial, patient, intervention, and outcome characteristics following predefined criteria. The primary outcome was all-cause mortality up to 2 years for the main analysis. Seven trials that randomly assigned 8020 participants to TAVI (4014 patients) and SAVR (4006 patients) were included. The combined mean STS score in the TAVI arm was 9.4%, 5.1%, and 2.0% for high-, intermediate-, and low surgical risk trials, respectively. Transcatheter aortic valve implantation was associated with a significant reduction of all-cause mortality compared to SAVR {hazard ratio [HR] 0.88 [95% confidence interval (CI) 0.78-0.99], P = 0.030}; an effect that was consistent across the entire spectrum of surgical risk (P-for-interaction = 0.410) and irrespective of type of transcatheter heart valve (THV) system (P-for-interaction = 0.674). Transcatheter aortic valve implantation resulted in lower risk of strokes [HR 0.81 (95% CI 0.68-0.98), P = 0.028]. Surgical aortic valve replacement was associated with a lower risk of major vascular complications [HR 1.99 (95% CI 1.34-2.93), P = 0.001] and permanent pacemaker implantations [HR 2.27 (95% CI 1.47-3.64), P < 0.001] compared to TAVI. CONCLUSION: Compared with SAVR, TAVI is associated with reduction in all-cause mortality and stroke up to 2 years irrespective of baseline surgical risk and type of THV system.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Siontis GCM, Overtchouk P, Cahill TJ, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J. 2019. PMID: 31329852. doi:10.1093/eurheartj/ehz275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。